What does positive surgical margins mean for Prostate Cancer

Prostate CancerMay 17, 2026Navis AI

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Understanding Positive Surgical Margins in Prostate Cancer

Great question—this is an important concept that affects treatment planning after surgery.

What Surgical Margins Mean

When a surgeon removes the prostate, the pathologist examines the tissue around the edges of the removed gland to see if cancer cells extend all the way to the cut edge. Think of it like cutting out a tumor from an apple—the "margin" is the rim of healthy tissue surrounding where you made your cut.

  • Negative margins = Cancer cells do NOT reach the edge (healthy tissue surrounds the cancer)
  • Positive margins = Cancer cells ARE present at the edge of the removed tissue (suggesting some cancer may have been left behind)

What Positive Margins Generally Indicate

A positive surgical margin suggests that:

  • Cancer cells may extend beyond what was surgically removed
  • There's a higher risk that microscopic cancer remains in the body
  • Additional treatment may be needed to address any remaining disease

However, a positive margin doesn't automatically mean the cancer will return—it's a risk factor that your oncologist will evaluate alongside other information.

How Doctors Typically Approach This

According to NCCN (National Comprehensive Cancer Network) Prostate Cancer Guidelines, when positive margins are found, oncologists consider:

  1. Other prognostic factors - PSA level before surgery, Gleason score, stage of disease
  2. Post-operative PSA levels - Whether PSA drops to undetectable levels after surgery
  3. Time to PSA recurrence - How quickly PSA rises again (if it does)
  4. Patient preferences and risk tolerance

General Treatment Approaches That May Be Considered

For patients found to have positive margins, doctors typically discuss options such as:

  • Observation with close monitoring - Regular PSA checks to watch for recurrence
  • Adjuvant radiation therapy - Radiation to the prostate bed to target any remaining cells (often recommended, especially with other high-risk features)
  • Salvage radiation - Radiation given later if PSA rises after surgery
  • Hormone therapy - Sometimes combined with radiation for higher-risk cases

Questions to Ask Your Oncologist

Since YOUR specific situation requires your doctor's complete evaluation, here are key questions:

  1. "Based on my positive margins AND my other pathology findings (Gleason score, PSA, stage), what is my recurrence risk?"
  2. "Do you recommend adjuvant radiation therapy, or would you prefer to monitor my PSA first?"
  3. "What PSA level or timeline would trigger additional treatment if we choose observation?"
  4. "Are there any other factors in my case that influence this decision?"
  5. "What are the side effects of the treatment options you're recommending?"

Important Context

According to the American Cancer Society and NCCN Guidelines, positive margins are relatively common after prostate surgery and don't necessarily mean treatment has failed. Many men with positive margins never experience PSA recurrence, while others benefit significantly from additional therapy. Your oncologist will determine the most appropriate approach based on YOUR complete clinical picture—including your age, overall health, other pathology findings, and personal preferences.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

This is general information.

Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.

Related Services

Services that may help with general for Prostate Cancer patients

Get guidance specific to your case

This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history: